Generic Combivent Respimat Availability
Last updated on Apr 10, 2025.
Combivent Respimat is a brand name of albuterol/ipratropium, approved by the FDA in the following formulation(s):
COMBIVENT RESPIMAT (albuterol sulfate; ipratropium bromide - spray, metered;inhalation)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: October 7, 2011
Strength(s): EQ 0.1MG BASE/INH;0.02MG/INH [RLD]
Is there a generic version of Combivent Respimat available?
No. There is currently no therapeutically equivalent version of Combivent Respimat available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Combivent Respimat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Patent 7,396,341
Issued: July 8, 2008
Inventor(s): Schyra; Michael et al.
Assignee(s): Boehringer Ingelheim International GmbH (Ingelheim, DE)A locking-stressing-mechanism with spring-actuated output drive and a counter with which an apparatus of this kind is fitted, accommodated in a two part housing the two parts of which are mounted to be rotatable relative to each other, can be blocked by means of a pre-stressed leaf spring. The leaf spring is initially accommodated in a recess in the wall of one housing part. As soon as the permitted number of actuations has been reached a push rod pushes the leaf spring out of its resting position. The leaf spring then jumps into a recess in the wall of the other housing part and the two housing parts can no longer be rotated relative to each other. The push rod may be mounted on the pointer of the counter. This blocking device can only be overcome by the application of a force which is sufficient to destroy the device. The device is suitable for blocking a high pressure atomiser or a needleless injector with which a fluid is atomised to form an aerosol or a fluid is injected into a biological tissue.
Patent expiration dates:
- October 10, 2026✓✓
- October 10, 2026
-
Device for clamping a fluidic component
Patent 7,837,235
Issued: November 23, 2010
Inventor(s): Geser; Johannes et al.
Assignee(s): Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)A fluidic component is arranged in an elastomeric shaped part, the contour of which is matched to the outer contour of the component and to the inner contour of a holder. The elastomeric shaped part is chamfered towards the fluidic component on its pressure side. When the holder is assembled, the elastomeric shaped part is deformed by a projection provided on a mating part and is put under uniformly distributed internal tension, after which the elastomeric shaped part surrounds the fluidic component to its full height.
Patent expiration dates:
- March 13, 2028✓✓
- March 13, 2028
-
Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Patent 8,733,341
Issued: May 27, 2014
Inventor(s): Boeck Georg & Spallek Michael
Assignee(s): Boehringer Ingelheim International GmbHAn atomizer and a method of dispensing and atomizing fluid into individual containers through a nozzle are proposed, where in order to improve the dosing accuracy, a preliminary amount of fluid, flushing the nozzle, is dispensed before each dose is dispensed.
Patent expiration dates:
- October 16, 2030✓✓
- October 16, 2030
-
Device for clamping a fluidic component
Patent 9,027,967
Issued: May 12, 2015
Inventor(s): Geser Johannes & Hausmann Matthias
Assignee(s): Boehringer Ingelheim International GmbHA fluidic component is arranged in an elastomeric shaped part the contour of which is matched to the outer contour of the component and to the inner contour of a holder. The elastomeric shaped part is chamfered towards the fluidic component on its pressure side. When the holder is assembled the elastomeric shaped part is deformed by a projection provided on a mating part and is put under uniformly distributed internal tension, after which the elastomeric shaped part surrounds the fluidic component to its full height.
Patent expiration dates:
- March 31, 2027✓✓
- March 31, 2027
More about Combivent Respimat (albuterol / ipratropium)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (17)
- Side effects
- Dosage information
- During pregnancy
- Drug class: bronchodilator combinations
- En español
Patient resources
Other brands
Professional resources
Other brands
Other formulations
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.